Innovative Bispecific Nanobody Targeting CEACAM5 and TNFRSF9 for Advanced Cancer Therapy

VHH-P346 is a humanized nanobody-based bispecific antibody that simultaneously targets CEA cell adhesion molecule 5 (CEACAM5) and TNF receptor superfamily member 9 (TNFRSF9). Currently in the Biological Testing stage, VHH-P346 is being developed as a potential therapeutic for cancer. By leveraging dual targeting of CEACAM5, a well-validated tumor-associated antigen, and TNFRSF9, an immune costimulatory receptor, VHH-P346 aims to offer a novel mechanism for tumor targeting and immune system activation. This innovative approach positions VHH-P346 as a promising candidate in the oncology pipeline, addressing critical challenges in cancer therapy.

Licensing Opportunity

VHH-P346 is available for out-licensing or collaborative development partnerships. We welcome inquiries from pharmaceutical and biotechnology partners interested in advancing this innovative immuno-oncology asset.

Development Phase

Modality

VHH-P346 utilizes an agonistic bispecific antibody format, combining a humanized IgG1 kappa monoclonal antibody against CEACAM5 with a nanobody (single-domain antibody) targeting TNFRSF9. The molecule is engineered with N297A mutations in the Fc domain and is fused via a flexible (G4S)4 linker, providing enhanced structural stability and precision in dual antigen engagement. The bispecific design, featuring a nanobody module, confers superior tissue penetration, high binding affinity, and increased molecular stability compared to conventional antibodies. These benefits are particularly relevant in cancer therapy, enhancing tumor accessibility and improving efficacy in targeting both tumor cells and the tumor microenvironment.

Target

CEACAM5 is a cell surface glycoprotein of the immunoglobulin superfamily, highly expressed on various epithelial tumor cells, particularly in colorectal, gastric, and lung cancers, while displaying limited presence in normal adult tissues. As a tumor-associated antigen, CEACAM5 is implicated in cell adhesion and immune modulation, making it a crucial marker and target for cancer therapies. TNFRSF9 is a member of the tumor necrosis factor receptor superfamily, predominantly expressed on activated T cells and natural killer cells. TNFRSF9 acts as an immune costimulatory molecule, crucial for T cell survival and antitumor immune responses. Targeting both CEACAM5 and TNFRSF9 enables VHH-P346 to selectively recognize and bind tumor cells while activating immune effector cells, positioning the program at the forefront of cancer immunotherapy strategies.

Mechanism of Action

VHH-P346 achieves its therapeutic effects by simultaneous binding to CEACAM5 on tumor cells and agonistically engaging TNFRSF9 on activated immune cells. The bispecific interaction bridges the tumor and immune compartments, enhancing immune cell activation and promoting cytotoxic responses against cancer cells. By modulating key signal transduction pathways associated with TNFRSF9 agonism, the nanobody-based design stimulates robust, tumor-specific immune activity. The modularity of the platform supports further development into antibody-drug conjugates, bispecific combinations, and other nanobody-based modalities, broadening its application within the immuno-oncology space.

Cancer

Cancer remains one of the leading causes of morbidity and mortality globally, affecting millions of individuals annually. Major cancer types include lung, colorectal, breast, prostate, and gastric cancers, each presenting unique clinical challenges. Conventional therapies, such as surgery, chemotherapy, and radiotherapy, are increasingly complemented by targeted and immunotherapeutic strategies. However, significant limitations persist, including drug resistance, toxicity, limited tumor specificity, and immune evasion by cancer cells. There is a critical need for innovative therapies that combine precise tumor targeting with effective immune modulation. VHH-P346, with its dual-action on CEACAM5 and TNFRSF9, offers the potential to address these unmet needs by improving tumor cell eradication and amplifying antitumor immune responses, representing an important advancement in cancer therapy.